started · updated
Eli Lilly expands manufacturing and oncology pipeline
Eli Lilly has commenced construction on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The new site is intended to produce injectable medicines, including the investigational drug retatrutide, to support the company's obesity medicine portfolio. The project is expected to create 850 permanent jobs and 2,000 construction jobs.
In a separate move to diversify its product offerings beyond diabetes and weight-loss treatments, Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash. The acquisition, which includes upfront payments and milestone-based incentives, aims to accelerate the development of treatments for rare blood cancers, specifically targeting mCALR-driven ET and MF.
The company's recent financial performance includes third-quarter revenue growth of 39% to $24.4 billion. Lilly has provided annual revenue guidance of $91 billion to $92 billion.
Entities
Calytrix Bio · Eli Lilly and Company · Lehigh Valley · Retatrutide